一种用于靶向载药的可降解纳米凝胶、制备方法及其应用
By using the spatial conformational complementary binding interface and three-dimensional cross-linking network between the biodegradable nanogel and EGFR protein, the problems of insufficient targeting and uncontrollable drug release of nanocarriers were solved, achieving high drug loading and controllable release, improving the efficacy of chemotherapy and reducing toxic side effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BEIJING INST OF TECH
- Filing Date
- 2026-06-16
- Publication Date
- 2026-07-17
AI Technical Summary
Existing nanocarriers have shortcomings in terms of targeting, drug release control, and drug loading capacity, leading to poor chemotherapy efficacy and toxic side effects.
The biodegradable nanogels, through the combination of functional monomers and biodegradable cross-linking agents, form a multi-site binding interface that is complementary to the spatial conformation of the EGFR protein, enabling targeted recognition and specific degradation in the tumor microenvironment. Combined with a three-dimensional cross-linked network structure, the nanogels facilitate drug loading and release.
It improves the targeting and drug loading capacity of the drug delivery system, enables controlled drug release, reduces systemic toxicity, and optimizes the effect of chemotherapy.
Smart Images
Figure CN122398722A_ABST